HRSA-26-092: Hereditary Hemorrhagic Telangiectasia (HHT) Center
Closed
This grant is closed. A newer notice from the same program is open now: Women's Initiative for Screening and Health (WISH) (HRSA-27-072). Status: Closes January 8, 2027 (62 days left). It is in our archive of Health Resources and Services Administration notices from 2026.
Health Resources and Services Administration offered grants of up to $2.9 million to any type of organization. It expected to make one award worth $2.9 million in total. Applications closed on July 10, 2026.
From the official notice on Grants.gov, last changed June 8, 2026. Checked November 7, 2026.
- Award ceiling$2.9 million
- Total funding$2.9 million
- Expected awards1
- Cost sharingNot required
- Funding typeCooperative Agreement
Other notices with this title
| Notice | Posted | Deadline | Status |
|---|---|---|---|
| HRSA-22-145 | March 18, 2022 | Closed May 17, 2022 | Closed |
Key dates
| Posted | June 8, 2026 |
|---|---|
| Deadline | July 10, 2026 |
| Archived by Grants.gov | August 30, 2026 |
Who can apply
This opportunity was open to any type of organization.
- State governments
- Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"
"Domestic" means the 50 states, the District of Columbia, the Commonwealth of Puerto Rico, the Northern Mariana Islands, American Samoa, Guam, the U.S. Virgin Islands, the Federated States of Micronesia, the Republic of the Marshall Islands, and the Republic of Palau.
Is this a realistic fit?
- Past Special Projects of Regional and National Significance awards averaged $1.6 million; this notice allows up to $2.9 million per award.
- No cost sharing or match is required.
What the grant funds
The purpose of the Hereditary Hemorrhagic Telangiectasia (HHT) Center Program is to reduce illness and death related to HHT by partnering with clinical center to expand access and coordination of care; creating innovative strategies that support clinicians with identifying and diagnosing HHT cases; and developing a de-identified, aggregate patient data registry to better understand this rare disease and its treatment outcomes.
Who has won Special Projects of Regional and National Significance grants before
From fiscal 2021 to 2025, Special Projects of Regional and National Significance (93.110) awarded $1.4 billion across 842 grant awards, an average of $1.6 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| Zero to Three National Center for Infants, Toddlers & Families | District of Columbia | 2 | $54.3 million |
| University Hospitals Cleveland Medical Center | Ohio | 1 | $51.5 million |
| Children's National Medical Center | District of Columbia | 1 | $37.2 million |
| University of North Carolina at Chapel Hill | North Carolina | 8 | $29.1 million |
| American Academy of Pediatrics | Illinois | 8 | $26.4 million |
Applying now
This notice no longer takes applications. Apply under the newer notice, HRSA-27-072, which is open now.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is HRSA-26-092 still open?
No. It closed on July 10, 2026. A newer notice is open: HRSA-27-072, closes January 8, 2027 (62 days left).
Who can apply for Hereditary Hemorrhagic Telangiectasia (HHT) Center?
Health Resources and Services Administration accepted applications from any type of organization. The notice adds further conditions, so read its eligibility section.
What is the deadline for Hereditary Hemorrhagic Telangiectasia (HHT) Center?
Closed July 10, 2026. Applications are no longer accepted; the program's newer notices are on this page when there are any.
How much funding is available?
Awards of up to $2.9 million each. About $2.9 million in total for one award.
Who has won Special Projects of Regional and National Significance grants before?
The largest recipients over five fiscal years were Zero to Three National Center for Infants, Toddlers & Families, University Hospitals Cleveland Medical Center, Children's National Medical Center. The program made 842 awards worth $1.4 billion in that time.
Similar open grants
- Single Source for the Continuation of the Caring for OutPatiEnts after Acute Kidney Injury (COPE-AKI) Scientific and Data Research Center (U01 Clinical Trial Required)
- Single Source for the Continuation of the Epidemiology of Diabetes Interventions and Complications (EDIC) Study Research Center (Collaborative U01 Clinical Trial Not Allowed)
- Data Coordinating Center for the Aging and Alzheimer’s Disease Mouse Brain Atlas (AD-MBA) (U24 Clinical Trial Not Allowed)
- Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required)
- Advanced Development and Validation of Emerging Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)
- Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)